Targeted Cancer Therapy Technologies

Lead product (Mab AR9.6) under development is for a novel target for cancer therapy discovered at University of Nebraska Medical Center;

• Target: truncated O-glycans on MUC16

Second product (ACP2127) under development is for a well-established target for cancer treatment

• Target: CDK/mTOR

Company highlights

• Combinatorial approach for optimal efficacy
• Diversified Product Pipeline with two proprietary technologies
• Experienced management and scientific team
• Access to academic and clinical expertise

Link to AmrutBio Presentation